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Abstract
The progression of cells from a normal differentiated state in which rates of proliferation and apoptosis are balanced to a tumorigenic and
metastatic state involves the accumulation of mutations in multiple key signalling proteins and the evolution and clonal selection of more
aggressive cell phenotypes. These events are associated with changes in the expression of numerous other proteins. This process of tumorigenesis
involves the altered expression of one or more TRP proteins, depending on the nature of the cancer. The most clearly described changes are those
involving TRPM8, TRPV6 and TRPM1. Expression of TRPM8 is substantially increased in androgen-dependent prostate cancer cells, but is
decreased in androgen independent and metastatic prostate cancer. TRPM8 expression is regulated, in part, by androgens, most likely through
androgen response elements in the TRPM8 promoter region. TRPM8 channels are involved in the regulation of cell proliferation and apoptosis.
Expression of TRPV6 is also increased in prostate cancer and in a number of other cancers. In contrast to TRPM8, expression of TRPV6 is not
directly regulated by androgens. TRPM1 is highly expressed in early stage melanomas but its expression declines with increases in the degree of
aggressiveness of the melanoma. The expression of TRPV1, TRPC1, TRPC6, TRPM4, and TRPM5 is also increased in some cancers. The level of
expression of TRPM8 and TRPV6 in prostate cancer, and of TRPM1 in melanomas, potentially provides a good prognostic marker for predicting
the course of the cancer in individuals. The Drosophila melanogaster, TRPL, and the TRPV1 and TRPM8 proteins, have been used to try to
develop strategies to selectively kill cancer cells by activating Ca2+ and Na+ entry, producing a sustained increase in the cytoplasmic concentration
of these ions, and subsequent cell death by apoptosis and necrosis. TRPV1 is expressed in neurones involved in sensing cancer pain, and is a
potential target for pharmacological inhibition of cancer pain in bone metastases, pancreatic cancer and most likely in other cancers. Further
studies are required to assess which other TRP proteins are associated with the development and progression of cancer, what roles TRP proteins
play in this process, and to develop further knowledge of TRP proteins as targets for pharmaceutical intervention and targeting in cancer.
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The processes involved in the transformation of normal cells
to tumorigenic cells and in tumour progression are complex and
are only partly understood (reviewed in [1,2]). At the
macroscopic and histological levels, tumorigenesis involves
the transition from normal cells to hyperplastic, dysplastic,
neoplastic and then to metastatic cells. This transition is caused
by the accumulation of mutations in certain key signalling
proteins, encoded by oncogenes and tumour suppressor genes,⁎ Corresponding author. Tel.: +61 8 8204 4260; fax: +61 8 8374 0139.
E-mail address: Greg.Barritt@flinders.edu.au (G. Barritt).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.05.006and the formation and selection by evolution of those cells
which can more aggressively compete in their local environ-
ment and, in the case of metastatic cells, in the environments of
other organs. Among the signalling pathways altered in
tumorigenesis those which enhance cell proliferation and
inhibit apoptosis are some of the most important. For example,
during the development of prostate cancer, where in the initial
stages cell proliferation is dependent on androgens, a small
number of cells become insensitive to androgens and resistant to
apoptosis (reviewed in [3,4]).
Many proteins in cancer cells exhibit increased or decreased
expression compared to their levels of expression in normal
cells. Some of these proteins, chiefly those encoded by onco-
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morigenesis and in the development of metastases, while others,
most likely including those involved in intracellular Ca2+
homeostasis (reviewed in [3,5]), are associated with cancer
progression but are not causative in further development of the
tumour and/or malignant cells (reviewed in [1]). Most cancers
are heterogeneous with respect to rates of growth and degrees of
aggression. This most likely reflects the fact that, for a given
cancer, there can be different combinations of oncogenes and
tumour suppressor genes which are mutated, different
sequences in which these mutations occur, and variations in
the time over which the mutations accumulate [1].
Several members of the TRP family of Ca2+- and Na+-
permeable channels (reviewed in [6,7]) showaltered expression in
cancer cells. The most studied are TRPM8, TRPV6, TRPM1 and
TRPV1 (Table 1). To date, most changes involving TRP proteins
do not involve mutations in the TRP gene but rather increased or
decreased levels of expression of the normal (wild type) TRP
protein, depending on the stage of the cancer. It is not yet possible
to say whether these changes in TRP expression are central steps
in the progression of the cancer or are secondary to other changes,
although the latter is most likely. Irrespective of the answer to this
question, several TRP proteins may prove to be valuable markers
in predicting the progress of cancers and are potential targets for
pharmaceutical treatment [8,12,13,20,25]. Also, since a number
of TRP channels are involved in sensory neurons, TRP channels
play a role in sensing pain in cancer (reviewed in [7]) and may be
targets in strategies to alleviate this pain [26,27].
The aim of this review is to summarise the observations
reported to date of changes in TRP protein expression
associated with cancer and its progression, to comment on
what this may mean in terms of cell physiology and pathology,
and to identify where TRP proteins can be potential targets for
diagnosis and therapeutic intervention. We are now only
beginning to understand how TRP proteins may be involved
in cancer. Furthermore, attempts to understand this involvement
are being made against the background of incomplete, and in
some cases very incomplete, knowledge of the normal
physiological functions of TRP proteins.
2. TRPM8
Cold/menthol-sensitive TRPM8 of the “melastatin” TRP
subfamily has recently emerged as an important player inTable 1
TRP proteins exhibiting altered expression in cancer cells
TRP protein Likely physiological function in
normal cells
Cancers investigated
TRPM1 Not determined Melanoma
TRPM8 Sensor for noxious cold,
and pain
Prostate, pancreas
TRPV1 Sensor for noxious heat, acid Prostate, bladder, colon, pan
TRPV6 Ca2+ across intestinal
epithelial cells
Prostate, breast, thyroid,
Colon, ovariancarcinogenesis, whose real significance, however, is only
beginning to unfold. TRPM8 is a so-called cold receptor
belonging to the melastatin (TRPM) subfamily of TRP channels
and is activated by cooling temperatures and menthol. Out of
the broad array of thermal receptors cold/menthol-sensitive
TRPM8 seems to be one of the most intriguing while still
remaining the least studied. The intrigue comes from the fact
that aside from sensory neurons, in which the role of TRPM8 in
mediating cold-evoked excitation is fairly well established
[28,29], it is most abundantly expressed in the prostate–a tissue,
which is not involved in temperature-dependent functions. In
fact, TRPM8 was first cloned from the human prostate as
prostate-specific gene [12], even before its role in the cold
sensation was established.
TRPM8 is a cation channel and in physiological conditions it
facilitates Ca2+ and Na+ entry across the plasma membrane,
leading to its depolarisation. In sensory neurons TRPM8 is
activated by cold stimuli. However, despite the numerous
hypotheses raised, the mechanisms of TRPM8 activation in
organs not exposed to ambient temperatures, and in particular in
prostate gland, remain poorly understood. Indeed, a model
ascribing TRPM8 activation to cold/menthol-induced shifts of
the channel voltage dependence towards physiological mem-
brane potentials has been proposed [30]. Although attractive in
its explanation of the temperature sensitivity, this model seems to
be insufficient to account for TRPM8 activation in the tissues not
exposed to any essential temperature variations. Moreover,
prominent rundown of TRPM8 activity in excised patches
[30,31] raises the possibility that some endogenous ligands
might be necessary for the channel activation. Phosphatidylino-
sitol 4,5-bisphosphate (PIP2) has been found to be such a factor,
as it was capable not only restoring menthol-activated TRPM8
current after its rundown in excised patches, but also of activating
the current independently of menthol [32]. These results suggest
the importance of this endogenous lipid signalling molecule in
sustaining the TRPM8 function. The functional importance of
the PIP2-dependent TRPM8 gating has thus become evident in
the cold sensation since any of the well-known PIP2 depletion
scenarios (e.g., activation of Gq/11-phospholipase C (PLC)
coupled receptors or Ca2+-dependent activation of some PLC
isoforms) would limit TRPM8 activation by shifting its gating
towards lower temperatures or higher voltages. However, the
possibility of channel activation (rather than desensitization)
with the involvement of PIP2 seems more remote.Changes in TRP expression References
Decreased expression in tumorigenic melanocytes [8–11]
Increased expression in androgen-insensitive
prostate cancer cells
[12–15]
creas Increased expression in prostate cancer,
colon cancer and pancreatic cancer
[16–19]
Decreased expression as bladder cancer progresses
and cells de-differentiate
[18]
Increased expression in cancer cells [20–24]
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proposed [33]. This mechanism involves stimulation by the
Ca2+-independent phospholipase A2 (iPLA2) thereby employing
chemical rather than physical (temperature change) signalling.
The authors have found that the active substances in the TRPM8
activation were lysophospholipids, lysophosphatidylcholine and
lysophosphatidylinositol, which are produced upon iPLA2
stimulation. The fact that receptor-mediated stimulation of
PLC will potentially produce oppositely directed effects on
TRPM8–inhibition via decreasing PIP2 levels and activation via
IP3-mediated store depletion–seems puzzling. It can be ex-
plained assuming differential roles for the two lipid messenger
pathways: the PIP2 primarily controlling TRPM8 desensitiza-
tion [32] with the lysophospholipids providing the main che-
mical activation input. Such an iPLA2-dependent mechanism of
TRPM8 activation has been confirmed in dorsal root ganglia
neurons, suggesting its ubiquitous character [34]. Interestingly,
several reports [35–37] indicate that TRPM8 is expressed not
only in the plasma membrane (PM) (called PMTRPM8), as
initially anticipated, but also in the endoplasmic reticulum (ER)
membrane (called ERTRPM8), where it operates as an ER Ca
2+
release channel involved in the activation of store-operated cal-
cium entry (SOCE) in response to cold/menthol stimulus. Since
the depletion of intracellular Ca2+ stores is known to be causally
associated with the stimulation of the iPLA2 [38], catalysing the
production of lysophospholipids, both PMTRPM8 and
ERTRPM8 could be activated by an iPLA2-related mechanism,
however, by store-independent or store-dependent mode of ac-
tivation, respectively.
While remaining at moderate levels in a normal prostate,
TRPM8 expression strongly increases in prostate cancer. For this
reason it has been proposed to be a pro-oncogenic actor in
prostate cancer cells [12]. Other non-prostatic primary human
tumours (breast, colon, lung, and skin) also become highly
enriched in TRPM8, although it is virtually undetectable in
corresponding normal tissues [12]. Thus, even this initial
information strongly pointed to much broader roles of TRPM8
beyond cold sensation, especially in the prostate and during
carcinogenesis. The role of TRPM8 in organs not exposed to
ambient temperatures, and especially in the prostate gland,
remains a gnawing mystery. However, the data accumulated in
the last three years allows the formulation of several hypotheses.
TRPM8 could function as a cold sensor in the prostate [39],
but may also be involved in other functions such as ion and
protein secretion, regulation of proliferation and/or apoptosis in
prostate epithelial cells (for review see [40]). Nevertheless, the
secretion of citric acid, prostate-specific antigen (PSA), acid
phosphatase, several enzymes, lipids and other products is the
major function of apical epithelial prostate cells. Therefore,
considering the specific TRPM8 expression in these cells, the
potential role of this channel in secretion has been suggested
[41]. Furthermore, the recent study of Mergler et al. has
confirmed this hypothesis on neuroendocrine pancreatic tumour
cells [15]. The authors have shown that TRPM8 activation
increases the secretion of neurotensin in these cells.
In normal prostate, trpm8 gene expression seems to be
directly controlled by androgen receptors [35,41] positioning itas a primary androgen-response gene [41]. Single-cell RT-PCR
and immunohistochemical experiments conducted on primary
human prostate cancer cells have shown that TRPM8 is mainly
expressed in androgen-dependent, apical secretory epithelial
cells, and that its expression becomes down-regulated in cells
losing the androgen receptor activity and regressing to the basal
epithelial phenotype [41]. Mature prostate epithelial cells are
non-proliferative cells which are highly sensitive to apoptotic
stimuli. (Due to the specific regulation of the expression of
genes belonging to the Bcl-2 family, anti-apoptotic Bcl-2 gene
expression is repressed whereas pro-apoptotic Bax gene
expression is stimulated by androgen receptors [42–44]).
In prostate cancer tumours, a significant difference in the
expression level of TRPM8 mRNA between malignant and
non-malignant tissue specimens has been detected [13]. This
was comparable to the currently used prostate cancer marker,
PSA, thus, qualifying TRPM8 as its potential competitor in
prostate cancer diagnosis and staging. A significant difference
in TRPM8 expression between human benign prostate hyper-
plasia and prostate cancer tissues is also obvious at protein level
[14]. According to Tsavaler’s hypothesis defining trpm8 as an
oncogene [12], TRPM8 over-expression and over activity in
circumscribed, androgen-dependent prostate cancer may be
correlated to the higher rate of growth of these cells compared to
normal ones [45,46]. During the transition to androgen
independence, TRPM8 is lost in a xenograft model of prostate
cancer and also in prostate cancer tissue from patients treated
preoperatively with anti-androgen therapy, suggesting that its
loss may be associated with a more advanced form of the
disease [47]. It has been demonstrated that LNCaP cells
resistant to anti-androgen bicalutamide treatment displayed a
reduced doubling time [14]. This is correlated with a decreased
expression of mRNA encoding the androgen receptor, TRPM8
and the Proliferating Cell Nuclear Antigen (PCNA), while anti-
apoptotic Bcl-2 mRNA expression is increased. All these data
reinforce the putative pro-proliferative role of TRPM8 in
androgen-dependent prostate cancer cells. Finally, it has also
been shown that both pharmacological activation of TRPM8
and siRNA-mediated TRPM8 silencing in LNCaP cells can
decrease the cell viability [35], probably by perturbing the
TRPM8-dependent intracellular Ca2+ homeostasis. However, it
is still not clear whether TRPM8 involvement in cell viability is
carried out through a pro-proliferative and/or an anti-apoptotic
mechanism.
The results of the very recent study of Prevarskaya’s team
suggest that, depending on its intracellular localization, TRPM8
could potentially regulate both proliferation and apoptosis in
prostate epithelial cells and, therefore, specific inhibition of
either ERTRPM8 or PMTRPM8may be considered depending on
the stage and androgen-sensitivity of the targeted prostate cancer
[48]. Using a combination of electrophysiology, Ca2+ imaging,
molecular and cell biology approaches (in studies of primary
cultures of normal and cancerous human prostate epithelial cells)
this team has shown that only highly differentiated prostate
epithelial luminal cells express functional plasma membrane
TRPM8 (PMTRPM8) channels. Importantly, prostate primary
epithelial cancer cells obtained from in situ prostate cancer
940 N. Prevarskaya et al. / Biochimica et Biophysica Acta 1772 (2007) 937–946biopsies were characterized by significantly larger PMTRPM8-
mediated current density than normal or benign prostate hyper-
plasia cells. This PMTRPM8 activity was abolished in de-dif-
ferentiated cells that had lost their luminal secretory phenotype.
In contrast, ERTRPM8 remained functional irrespective of the
differentiation status of prostate cells. This differential regula-
tion of TRPM8 activity has been explained by the complex
regulation of ERTRPM8 and PMTRPM8 isoforms by androgen
receptors.
In view of the fact that the role of TRPM8 in LNCaP cell
survival has recently been demonstrated [35], the authors
speculate that any shift in the balance between classical TRPM8
and ER-specific TRPM8 isoform expression may modify the
Ca2+ signature, thus increasing the potential for either
proliferation or apoptosis. Indeed, alterations in Ca2+ home-
ostasis increase proliferation [49–51], as well as induce dif-
ferentiation [52] and apoptosis [53,54] (for review see [3]).
Considering that ER Ca2+ content is known to regulate cancer
cell growth, the finding that ERTRPM8 is functional in de-
differentiated prostate cancer cells with down-regulated andro-
gen receptor provides new insight into the role of this channel in
prostate cancer progression and may be of great importance in
developing therapeutic strategies for metastasized prostate
cancer.
3. TRPM1
TRPM1 (initially called melastatin) was discovered in B-16
mouse melanoma cell lines as a result of differential display
analysis [8]. Heterologous expression of TRPM1 in HEK293
cells has been shown to lead to an increase in the cytoplasmic
free Ca2+ concentration ([Ca2+]cyt) at the normal extracellular
Ca2+ concentration ([Ca2+]ext), and a corresponding increase or
decrease in [Ca2+]cyt when [Ca
2+]ext was increased or decreased
compared to the absence of such changes in control HEK cells
[55]. This suggests that when heterologously expressed,
TRPM1 is constitutively active (active in the absence of
addition of any known activator). Ca2+ entry through TRPM1 is
inhibited by La3+ and Gd3+ [55]. To date, no electrophysiolo-
gical studies of TRPM1 have been reported. Several splice
variants of TRPM1 have been detected, including one
designated TRPM1-S (short, 500 amino acids). TRPM1-S
interacts with full length TRPM1 (TRPM1-L, long, 520 amino
acids) and there is some evidence to indicate that this interaction
prevents the trafficking of TRPM1-L to the plasma membrane,
and may play a role in regulation of Ca2+ entry through TRPM1
[55,56]. While it has been suggested that TRPM1 may be
involved in the regulation of cell proliferation [25], the cellular
and biological roles of TRPM1 are not well understood.
Studies of TRPM1 expression in B-16 mouse melanoma cell
lines have shown that poorly metastatic variants, such as B-16-
F1, express higher levels of TRPM1 mRNA compared to highly
metastatic variants, such as B-16-F10 [8]. In specimens of
human melanoma tissue, Duncan and colleagues, using in situ
hybridisation, found high levels of TRPM1 expression in
benign tissue (nevi), decreased expression in primary melano-
mas, and no detectable mRNA in metastatic melanomas [8].TRPM1 mRNA expression appears to correlate with the state of
melanocytic tumour progression, thickness of the tumour, and
the degree of aggression, with low or undetectable TRPM1
mRNA expression in aggressive tumours [9–11].
These observations have led to the suggestion that the trpm1
gene is a tumour suppressor [9–11]. It has also been suggested
that the level of expression of TRPM1 mRNA may be a
prognostic marker for the development of melanoma metastasis,
and hence, may permit the prediction of the development of
non-metastatic or metastatic melanomas [8,25].
Studies of the regulation of expression of TRPM1 in mela-
nocytes and melanoma cells have provided evidence that
TRPM1 expression is linked to the state of cell differentiation,
and is regulated by the microphthalmia transcription factor
(MIRF). Thus, the treatment of human pigmented metastatic
melanoma cells with hexamethylene bisaretamide, an inducer of
cell differentiation, led to an increase in TRPM1 mRNA ex-
pression [9]. Other studies have shown that the promoter region
of the TRPM1 gene contains binding sites for microphthalmia,
indicating that TRPM1 expression is likely to be regulated by
MIRF. This transcription factor also regulates expression of a
number of other melanoma cell proteins [57–59].
4. TRPV6
Studies with heterologously expressed TRPV6 have shown
that this channel has a high selectivity for Ca2+ compared to
Na+ [60]. Results of experiments with heterologously expressed
TRPV6 using fura-2 to measure [Ca2+]cyt suggest that TRPV6 is
constitutively active, but under physiological conditions using
perforated patch-clamping no constitutive current was observed
[61,62]. Ca2+ entry through TRPV6 can be enhanced by a
decrease in [Ca2+]cyt or removal of extracellular divalent ca-
tions, leading to the conclusion that TRPV6 Ca2+ entry is
regulated by both extracellular and intracellular Ca2+ [61,62].
Heterologous expression of TRPV6 in HEK293 cells leads to an
increase in the rate of cell proliferation but it is not clear if this is
due to enhanced Ca2+ entry through TRPV6 [63]. TRPV6 is
expressed in the intestine, kidney, placenta and pancreas
[64,65]. One of the biological functions of TRPV6 is to me-
diate transcellular Ca2+ movement across epithelial cells of the
gut, kidney and placenta [24,65,66]. Consistent with this is the
observation that 1,25-dihydroxy cholecalciferol (vitamin D)
substantially increases TRPV6 expression [67].
When compared with normal tissue or cells, the expression
of TRPV6 mRNA (measured using semi-quantitative or real
time quantitative RT-PCR) and/or expression of the TRPV6
protein (measured by immunofluorescence) is substantially
increased in prostate cancer tissue, and in human carcinomas of
the colon, breast, thyroid, and ovary [20,21,23,64]. Increased
expression of TRPV6 mRNA compared with that in normal
cells is also observed in the LNCaP and PC-3 prostate cancer
cell lines [23], in SW480 colorectal cancer cell lines [23] and in
the K-562 chronic myelogenous leukaemia cell line [24].
Increased expression of TRPV6 is not observed in pancreatic
carcinoma and some other cancers [64] indicating that TRPV6
is not a general marker for tumorigenic cells [25,64].
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made in prostate cancer. In healthy and benign human prostate
tissue the expression of TRPV6 mRNA is very low or is not
detectable [20,64]. Studies with prostate cancer tissue obtained
from biopsies or resections show substantial expression of
TRPV6 mRNAwhich increases with the degree of aggressive-
ness of the cancer, assessed by the Gleeson score (grading of the
pathological stage) and the degree of metastasis outside the
prostate [20,23]. These observations have led to the suggestion
that the level of expression of TRPV6 could be used as a marker
to predict the clinical outcome of prostate cancer [20,25].
As mentioned above, TRPV6 is expressed in the LNCaP
human prostate cancer cell line. Prevarskaya’s team have
recently shown that TRPV6 is directly involved in the control of
proliferation in LNCaP cells by decreasing: (i) proliferation
rate; (ii) cells accumulation into S-phase of the cell cycle; and
(iii) proliferating cell nuclear antigen (PCNA) expression [68].
This team has demonstrated that Ca2+ uptake into LNCaP cells
is mediated by TRPV6, with the subsequent downstream
activation of nuclear factor of activated T cells (NFAT). The
possible role of androgens in the regulation of TRPV6 mRNA
expression remains unclear. Previous studies have shown that
the androgen receptor agonist dihydrotestosterone inhibits
TRPV6 expression while the androgen receptor antagonist
becalutamide increases TRPV6 expression [23,69,70]. How-
ever, TRPV6 expression has not been identified in androgen-
insensitive prostate cancer cell lines DU-145 and PC-3 [20] and,
moreover, Lehenkyi et al. have shown that TRPV6 expression
in LNCaP cells is regulated by androgen receptor, however in a
ligand-independent fashion [68]. To date, little is known about
whether the observed increased expression of TRPV6 mRNA
and protein in prostate cancer cells is associated with increased
Ca2+ and Na+ entry through functional TRPV6 channels, and
what the physiological and pathological consequences might be
[25]. However, it has been shown from studies with LNCaP
cells that TRPV6 is involved in the current activated by
intracellular stores depletion [69–73] and in the Ca2+ uptake in
prostate cancer cells [68].
5. Other TRP proteins
Several other TRP proteins, TRPC1, TRPC6, TRPM5 and
TRPV1, have been reported to be associated with tumorigenesis
and the growth and progression of cancer cells. It is likely that
further studies will reveal associations between other TRP
proteins and cancer cells. In the transition from androgen-
dependent to androgen-independent prostate cancer, the expres-
sion of TRPC1 is decreased [7]. This may have physiological
and/or pathological consequences since it has been suggested
that TRPC1 is a component of SOCs in prostate cancer cells
[69,72,74]. In studies of primary human prostate cancer
epithelial cells, in which TRPC6 expression was ablated using
antisense hybrid deletion, Ca2+ entry, activation of NFAT and
cell proliferation activated by α-adrenergic receptors were
inhibited. It was suggested that Ca2+ entry through TRPC6
channels is required for NFAT activation and cell proliferation
[51].Suguro et al. have studied the CD5+ subgroup of diffuse large
B-cell lymphomas which comprise about 30% of non-Hodg-
kin’s lymphomas [75]. CD5+ is associated with poor prognosis.
TRPM4 mRNA expression was found to be increased in CD5+
lymphomas along with increased or decreased expression of a
number of other genes. It was suggested that TRPM4 is one of
several genes which constitute a “CD5 signature” which can be
used as a prognostic clinical marker.
Indirect genetic evidence suggests that altered expression of
TRPM5 may be associated with tumorigenesis. Alterations in
region 11p15.5 of the human chromosome are known to be
associated with Beckwith–Wiedemann syndrome and with a
predisposition to neoplasias including Wilms’ tumours, rhaboid
tumours, and rhabdomyosarcomas (reviewed in [76]). In a study
of candidate genes in the 11p15.5 region, Prawitt et al. identified
TRPM5 as one of the genes in this region of DNA [76].
Moreover, TRPM5 mRNAwas found to be expressed in a large
proportion of Wilms’ tumours and rhabdomyosarcomas [76].
Increased expression of TRPV1 has been found to be
associated with prostate cancer and cancers of the colon,
pancreas and bladder [16–19]. Substantial TRPV1 expression
has been observed in the LNCaP and PC-3 prostate cancer cell
lines [19]. Other studies have shown that TRPV1 is expressed in
the normal urothelium of the bladder. Moreover, the amount of
TRPV1 decreased in cancerous urothelium with a progressive
decrease in TRPV1 expression observed as the carcinoma
progresses to a more aggressive stage and the cells become
more de-differentiated [18].
Immunohistochemical studies have shown that TRPV1 is
expressed in colon adenocarcinoma [16]. Moreover, it has been
shown that the concentration of extracellular polyamines, a
TRPV1 agonist, in tissues of the gastrointestinal tract increases
during inflammation and cancer [77]. This raises the possibility
that TRPV1 may be activated by polyamines in colon cancer,
possibly contributing to cancer pain. TRPV1 may also play a
role in cancer pain in pancreatic cancer. Thus, expression of
TRPV1 is increased in pancreatic cancer and in pancreatitis.
The extent of TRPV1 expression was found to be related to the
intensity of pain reported by cancer patients, but this relation-
ship was not found in patients with chronic pancreatitis [17].
6. TRP channels as potential pharmaceutical targets in
cancer treatment
Two aspects of the properties of TRP proteins and the
association of increased or decreased expression of a given TRP
protein with cancer and the progression of cancer have been
used to try to develop strategies to kill cancer cells. One aspect
uses Ca2+ and Na+ entry through TRP channels expressed in
cancer cells which leads to a sustained high [Ca2+]cyt and
cytoplasmic Na+ concentration ([Na+]cyt) which kills the cells
by apoptosis and necrosis. This strategy requires the selective
expression and activation of a given TRP channel in the targeted
cancer cells. New strategies for killing cancer cells by activation
of the apoptotic pathway are valuable, since for many cancer
cells, including androgen-insensitive prostate cancer cells, the
normal pathways of apoptosis are inhibited and the cells are
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the high expression of some TRP channels in cancer cells to
provide a target for delivering a toxic payload (e.g. a radioactive
nuclide or toxic chemical) to the cancer cells. Recognition of the
TRP protein could be achieved through a tight-binding agonist
or an anti-TRP antibody (reviewed in [82]).
There are several examples in normal physiology and
pathophysiology where Ca2+ and Na+ entry through TRP
channels leads to cell death [83,84]. Some studies have
extended this observation to use Ca2+ and Na+ entry through
TRP channels as a strategy to kill cancer cells. The mechanisms
which lead to Ca2+- and Na+-induced cell death by apoptosis
and necrosis are complex. They probably include initiation ofFig. 1. Development of strategies to kill cancer cells using sustained Ca2+ and Na+ ent
Ca2+- and Na+-induced cell death resulting from sustained Ca2+ and Na+ entry, inc
(B) Heterologous expression of TRPV1 in LNCaP prostate cancer cells under the con
inserted into the Ad-Track plasmid (which can express EGFP), and transiently transf
endogenous TRPV1 in extracts of dorsal root ganglia, and in LNCaP cells transfecte
immunofluorescence (panels 1 and 2) and GFP fluorescence (panels 3 and 4) (Zhang
heterologously expressed in LNCaP cells with capsaicin leads to a substantial decre
unpublished results). (D) A representation of the structure of a pro-drug [96] in whi
peptide (Zhang, R., Voelker, N. and Barritt, G.J. unpublished results). The serine pro
Ser–Leu–capsaicin which can potentially bind to the TRPV1 ligand site.the intracellular pathway of apoptosis and pathways of necrosis
by the sustained high [Ca2+]cyt which likely leads to the
activation of proteases, phospholipases, and the loss of
mitochondrial function due to the uptake of large amounts of
Ca2+ (Fig 1A) [53,78,85,86]. The sustained increase in [Na+]cyt
most likely contributes to the initiation of necrosis by inducing
cell swelling, the activation of proteases and phospholipids, and
changes in membrane potential and ion transporters involved in
volume regulation [87–89]. The strategy of using sustained
elevated [Ca2+]cyt to kill cells builds on earlier studies of Isaacs
and others, which employed the SERCA inhibitor thapsigargin
to release Ca2+ from the ER which, in turn, induces ER stress
and activates sustained Ca2+ entry through SOCs [90].ry through plasma membrane TRP channels. (A) A scheme showing pathways of
luding the concentrations of Ca2+ in mitochondria (Ca2+M) and ER (Ca
2+
ER).
trol of the CMV promoter. TRPV1 was cloned from DNA from nodose ganglia,
ected into LNCaP prostate cancer cells. (a) Western blot showing expression of
d with Ad-Track-CMV-TRPV1. (b) Images showing localisation of TRPV1 by
, R. and Barritt, G. unpublished results). (C) The activation of TRPV1 channels
ase in cell numbers (detected by GFP fluorescence) (Zhang, R. and Barritt, G.
ch capsaicin is covalently linked to a prostate specific antigen (PSA)-cleavable
tease activity of PSAwould be expected to hydrolyse the Gln–Ser bond to yield
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melanogaster photoreceptor TRPL channel to kill prostate
cancer cells. When heterologously expressed in some animal
cells, TRPL is constitutively active and permits the entry of Ca2+
and Na+ [91–93]. TRPL was heterologously expressed in
LNCaP and PC-3 prostate cancer cells under the control of the
CMVpromoter, a prostate specific androgen promoter construct,
or the inducible doxycycline-sensitive Tet-On promoter system.
Expression of TRPL led to constitutive Ca2+ entry, an increase in
[Ca2+]cyt and cell death by apoptosis and necrosis [87,89]. A
similar strategy involving heterologous expression of TRPV1,
which has the advantage of being activated by a ligand (e.g.
capsaicin), has also been tested with prostate cancer cells (Fig.
1B and C) (Zhang, L and Barritt, G J, unpublished results) (see
also [94]). These strategies offer the potential to selectively kill
prostate (and other) cancer cells. Strategies to provide selectivity
include the use of prostate-specific promoters to selectively
express the TRP channel in prostate cancer cells [87], and
delivery of agonists as a “pro-drug”. For example, an inactive
conjugate of the required TRP agonist with a peptide which is
cleavable by the proteolytic activity of prostate specific antigen
(Fig 1D) [90,95,96].
Studies with some other cancers also suggest that TRPV1
may be a useful target for killing cancer cells through a
sustained increase in [Ca2+]cyt and [Na
+]cyt. Resinferatoxin, an
analogue of capsaicin and an agonist of TRPV1, was shown to
cause inhibition of mitochondrial function and induce apoptosis
in pancreatic cancer cells, presumably via endogenous TRPV1
channels in the plasma membrane [17]. It was suggested that
vanilloids might be used to treat pancreatic cancer [17].
Lignesti and colleagues tested the ability of various plant
cannaboids, which bind to the cannaboid (CB) and TRPV1
receptors, to inhibit tumour cell growth [97]. Using a panel of
tumour cell lines as well as a xenograft mouse model of breast
cancer (MDA-MB-231 cells), they found that cannaboids, of
which cannabidiol was the most potent, inhibited cell and
tumour growth. They suggested cannaboids may act through
CB2 receptors and the TRPV1 channels. Endogenous canna-
boids play an important role in the neuronal control of the
digestive tract [98], and Izzo and Coutts have suggested that the
pharmacological administration of cannaboids, which, in part,
act through TRPV1 channels could be used to treat colon cancer
[98].
As discussed above, TRPM8 is expressed in prostate cancer
cells, its expression decreases as the cancer progresses to a more
metastatic state, and hence TRPM8 is considered potentially
useful for both the diagnosis of prostate cancer and as a target
for cancer therapy. The treatment of prostate cancer would be
greatly enhanced by better prediction of the course of the
disease, including the likelihood of the development of
androgen insensitivity and metastases, and by new strategies
to kill androgen-insensitive prostate cancer cells which, as
mentioned above, are resistant to apoptosis [78–80].
Recently a menthol analogue and TRPM8 agonist, WS-12,
has been synthesised and characterised. WS-12 has an affinity
for the TRPM8 menthol binding site which is about 2,000 times
higher than that for menthol itself [4]. Incorporation of a fluorineatom into WS-12 resulted in an analogue (WS-12F) which
activated TRPM8 by 75% of the activation induced by WS-12
and retained a high affinity for TRPM8. It has been suggested
that WS-12 and WS-12F offer potential possibilities in the
detection of micro metastases and in killing prostate cancer cells.
Thus, the incorporation of 18F into WS-12 may permit radio-
imaging of micro metastases, and/or the delivery of a radio-
nuclide, which could kill target cells, to specific locations of
cancer cells in both the prostate and in metastases [4].
7. TRP channels as targets for the management of cancer
pain
Pain is a major issue for many cancer patients, and an im-
portant consideration in the care of these patients. The TRPV1,
TRPV3, TRPV4, TRPA1 and TRPM8 proteins are involved in
the detection of a variety of painful stimuli by nociceptive
tumours (reviewed in [7]). The results of several studies suggest
that TRPV1 is a useful pharmacological target for the treatment
of cancer pain. TRPV1 is expressed in nociceptors that detect
multiple pain-producing stimuli including heat and extracellular
H+ (acid) (reviewed in [7]). Hartel et al. have provided evidence
that expression of TRPV1mRNA is higher in pancreatic tissue in
those patients who reported higher levels of pain from pancreatic
cancer, and have suggested that the pharmacological application
of vanilloids might be useful for the treatment of neurogenic pain
in patients with pancreatic cancer [17]. In a mouse model of
cancer pain, the TRPV1 antagonist capsazepine was found to
inhibit hyperalgesia induced by tumour cell inoculation [99]. The
authors suggested that altered TRPV1 expression may be
responsible for the tumour-induced hyperalgesia.
In a mouse model of thermal hyperalgesia induced by tibial
osteosarcoma, capsazepine, a TRPV1 antagonist, and resinfer-
atoxin, a TRPV1 agonist, both inhibited osteosarcoma induced
hyperalgesia [26]. This somewhat surprising result suggested an
involvement of TRPV1 in osteosarcoma-induced hyperalgesia.
Ghilardi et al. found that TRPV1 is expressed in sensory neurons
that innervate the mouse femur, and using an in vivomousemodel
of bone cancer pain showed that the acute or chronic adminis-
tration of a TRPV1 antagonist, or disruption of the TRPV1 gene
led to a reduction of nocifensive behaviours [27]. The results of
both these studies suggest that further evaluation of TRPV1 as a
pharmaceutical target for the reduction of pain due to bone cancer
metastasis will prove beneficial [26,27].
8. Conclusions
From the discussion above the following conclusions can be
drawn. (i) TRPM8, TRPM1, and TRPV6 are highly expressed in
cancer cells and the amount of protein expressed changes with
progression from normal to tumorigenic to metastatic cells. The
expression of some other TRP channels, including TRPC1,
TRPC6, TRPM5 and TRPV1 is also increased in cancer tissues.
So far, there is no evidence to indicate that the expression of a
given TRP protein is consistently increased or decreased in
many different cancers, although further studies may show this is
the case for some TRP proteins, for example, TRPM8. (ii) It has
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TRPM1 a tumour suppressor gene, but further experiments are
required to test these hypotheses. (iii) Many of the physiological
and pathophysiological roles of the TRP proteins which are
expressed at high levels in cancer tissue are still to be elucidated.
This task is presently mademore difficult because, for some TRP
channels, little is known of their functions in normal cells. The
roles of TRP channels in cancer progression may involve
changes in intracellular Ca2+ and Na+, although effects on Ca2+
would be complex since the expression of some TRP proteins
increases while that of others decreases as cancer progresses
[25]. Another likely possibility is that some of the effects of TRP
proteins in cancer cells are exerted by their interactions with
other intracellular proteins [25]. Elucidation of the cellular
functions of TRP channels in tumorigenesis and in cancer cells
might be achieved by ablation of a given TRP protein, for
example, by use of a non-functional TRP mutant [25]. (iv)
TRPM8, TRPM1 and TRPV1 are potential diagnostic markers
for the prognosis of tumour development especially the degree
of tumour aggression, and are potential targets for pharmaceu-
tical interventions. Such interventions may involve use of the
TRP protein as a recognition site for antibody-mediated delivery
of a toxic pay load, or possibly more directly through selective
activation of the TRP channel to induce sustained Ca2+ and Na+
entry, and subsequent necrosis and apoptosis.
It is predicted that there will be considerable further progress
in understanding changes in TRP channel expression in cancer
cells in the next few years as knowledge of both the molecular
events involved in cancer progression and the physiological
functions of TRP channels increases. One of the main
challenges will be gaining an understanding of whether the
involvement of a given TRP channel is part of the causative
mechanisms involved in cancer progression or is associated in a
secondary manner with these mechanisms and changes.
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